Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eucomed sets up PR (public relations) campaign for France:

This article was originally published in Clinica

Executive Summary

Eucomed, the European medical devices industry association, is preparing to launch a healthcare technology public relations campaign in France. It will wait, however, until the presidential and parliamentary elections in May/June are over and start its campaign in the post-election period of autumn 2002. This will be the next in a series of national European programmes aimed at raising the profile of the industry. The association is also planning a PR campaign in Germany that will focus on cost-benefit data to underline the value of medical devices. This campaign aims to target the "quality press" more than has hitherto been the case, in the run up to the presidential elections that are scheduled for September. Eucomed is planning to target Brussels soon.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel